Atezolizumab with bevacizumab provided improved progression-free survival over sunitinib in patients with untreated metastatic renal cell carcinoma.
The China National Medical Products Administration has approved the combination of atezolizumab (Tecentriq) plus bevacizumab (Avastin) for use in patients with unresectable hepatocellular carcinoma (HCC) who have not received previous systemic therapy.1 The regulatory decision was based on data from the ...
Atezolizumab plus bevacizumab (A+B) as first-line systemic therapy for advanced hepatocellular carcinoma (HCC): A multi-institution analysis of patient out... Atezolizumab plus bevacizumab (A+B) as first-line systemic therapy for advanced hepatocellular carcinoma (HCC): A multi-institution analysis ...
2022 Atezolizumab Plus Bevacizumab as First-line Treatment for Patients With Metastatic Nonsquamous Non–Small Cell Lung Cancer With High Tumor Mutation BurdenA Nonrandomized Controlled Trial Mariano Provencio, MD, PhD1; Ana Laura Ortega, MD2; Juan Coves-Sarto, MD3; et al Virginia Calvo, MD, Ph...
We herein report a 73-year-old man with advanced stage HCC who developed fatigue during treatment with atezolizumab–bevacizumab combination therapy. Computed tomography identified intratumoral hemorrhage within the HCC metastasis to the right fifth rib metastasis of HCC, which was confirmed on emergency...
由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦! 已完结 文献求助详情标题Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma 阿替唑单抗联合贝伐单抗治疗不能切除的肝癌 ...
(Atezo) plus bevacizumab (Bev) is the preferred first-line treatment of HCC patients with BCLC stage C.20–22 The IMbrave150 trial established the position of Atezo-Bev as the first-line treatment for advanced HCC.20 However, the patients with large uHCC were underrepresented in the IMbrave...
Bevacizumab and breast cancer: current therapeutic progress and future perspectives Critical appraisal of bevacizumab in the treatment of metastatic colorectal cancer First-Line Atezolizumab Effective in Bladder Cancer Optimizing the treatment of bevacizumab as first-line therapy for human epidermal growth fact...
paclitaxel (ABCP) versus the standard-of-care bevacizumab plus carboplatin plus paclitaxel (BCP) in chemotherapy-naive patients with non-squamous non-small-cell lung cancer. Here, we report the efficacy of ABCP or atezolizumab plus carboplatin plus paclitaxel (ACP) versus BCP in key patient ...
A comprehensive review of clinical data of atezolizumab plus bevacizumab for the treatment of unresectable HCC.